logo-loader

Imugene's Leslie Chong welcomes strong support for its $90 million placement

Published: 22:32 28 Jul 2021 EDT

Imugene Ltd's Leslie Chong speaks to Proactive's Andrew Scott following the news of a $90 million placement to new and existing institutional and sophisticated investors as well as a share purchase plan for existing eligible shareholders to raise up to a further $5 million. She says the capital raised will be used to fund their clinical trial pipeline through to the end of 2025.

Imugene doses first patient in PD1-Vaxx combination trial

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with...

on 31/5/23